Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Teijin Limited (3401.T)
Tokyo, JP
Teijin Limited, a Japanese conglomerate established in Tokyo in 1918, operates on a global scale across diverse sectors. Its core businesses encompass advanced materials, including fibers, films and sheets, and composites, as well as significant operations in healthcare and information technology. The company's materials division provides a comprehensive range of products such as high-performance aramid, carbon, and oxidized PAN fibers, along with various polyethylene materials. This segment also offers specialized items like polytrimethylene telephthalate products, artificial leather materials, polyester nanofibers, and recycled polyester fibers. Its offerings extend to polycarbonate, high-density polyethylene porous, and microporous films and sheets, in addition to PC and polyphenylene sulfide resins, molded parts, and additives. Teijin is also a specialist in composite materials, notably developing lightweight glass and carbon fiber reinforced solutions designed for the automotive industry. In the healthcare sector, Teijin develops pharmaceuticals aimed at treating bone and joint, respiratory, and cardiovascular and metabolic diseases, among others. Furthermore, it supplies an extensive array of medical devices and services, including home oxygen therapy equipment, non-invasive positive pressure ventilation systems, rehabilitation tools, and devices for sleep-disordered breathing. The company also provides a sonic accelerated fracture healing system, community-based integrated care systems, orthopedic implantable devices, and functional food ingredients. Within its IT operations, Teijin offers innovative solutions such as Recopic, a radio-frequency identification (RFID) technology tailored for efficient inventory management. Beyond its product lines, the company is actively involved in engineering solutions, tackling critical global challenges related to environmental pollution, ensuring energy supply stability, and addressing the impact of an aging workforce population.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.05% | +7.51% | -0.12% | +1.36% | +33.09% | +27.58% | +48.63% | +19.02% | -7.44% | -7.24% | -8.72% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 4 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Conglomerates: +6.1%-13.2% Q1'26: -14.5% (vs Q1'25)
-
EPS growth Conglomerates: +16.9%-410.1% Q1'26: -28.2% (vs Q1'25)
-
FCF margin FCF growth · Conglomerates: +35.9%-7.6% Q1'26: +7.5% (vs Q1'25)
-
EBIT margin Conglomerates: +9.0%-7.9% Q1'26: -12.7% (vs Q1'25)
-
ROIC Conglomerates: +4.7%-11.6% Q1'26: -18.1% (vs Q1'25)
-
Share dilution Conglomerates: +0.0%+0.1% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Conglomerates: 1.28×-4.85× Q1'26: -3.10× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 5 Rev. Ana. 1 EPS Ana. |
Mar 2027 5 Rev. Ana. 5 EPS Ana. |
Mar 2028 5 Rev. Ana. 5 EPS Ana. |
Mar 2029 3 Rev. Ana. 3 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
786.17B
est: 783.38B (+0.4%)
|
790.75B
est: 791.40B (-0.1%)
|
741.29B
est: 741.29B (+0.0%)
|
834.99B
est: 831.01B (+0.5%)
|
888.59B
est: 884.38B (+0.5%)
|
853.75B
est: 854.67B (-0.1%)
|
836.51B
est: 809.47B (+3.3%)
|
926.05B
est: 910.82B (+1.7%)
|
1.02T
est: 1.03T (-0.7%)
|
960.46B
est: 1.06T (-9.3%)
|
1.01T
est: 1.01T (-0.6%)
|
861.14B
855.01B – 867.98B
-14.9% YoY
|
880.58B
854.71B – 928.75B
+2.3% YoY
|
942.96B
877.09B – 1.01T
+7.1% YoY
|
956.25B
944.38B – 968.13B
+1.4% YoY
|
1.03T
975.83B – 1.09T
+7.5% YoY
|
| EBITDA |
82.12B
est: 62.61B (+31.1%)
|
106.02B
est: 63.26B (+67.6%)
|
98.11B
est: 59.25B (+65.6%)
|
115.48B
est: 66.42B (+73.9%)
|
107.55B
est: 70.69B (+52.1%)
|
107.16B
est: 68.31B (+56.9%)
|
106.77B
est: 64.70B (+65.0%)
|
113.02B
est: 72.80B (+55.3%)
|
91.63B
est: 81.96B (+11.8%)
|
64.01B
est: 84.40B (-24.2%)
|
-7.85B
est: 80.62B (-109.7%)
|
68.63B
68.14B – 69.17B
-14.9% YoY
|
70.18B
68.11B – 74.01B
+2.3% YoY
|
75.15B
69.90B – 80.24B
+7.1% YoY
|
76.21B
75.26B – 77.15B
+1.4% YoY
|
81.88B
77.77B – 86.92B
+7.5% YoY
|
| EBIT |
39.09B
est: 6.71B (+482.9%)
|
67.13B
est: 6.77B (+890.9%)
|
56.51B
est: 6.35B (+790.6%)
|
69.82B
est: 7.11B (+881.5%)
|
60.00B
est: 7.57B (+692.5%)
|
56.21B
est: 7.32B (+668.2%)
|
54.93B
est: 6.93B (+692.7%)
|
44.21B
est: 7.80B (+467.0%)
|
12.86B
est: 8.78B (+46.5%)
|
-14.03B
est: 6.99B (-300.8%)
|
-78.88B
est: 6.67B (-1,282.2%)
|
5.68B
5.64B – 5.73B
-14.9% YoY
|
5.81B
5.64B – 6.13B
+2.3% YoY
|
6.22B
5.79B – 6.64B
+7.1% YoY
|
6.31B
6.23B – 6.39B
+1.4% YoY
|
6.78B
6.44B – 7.19B
+7.5% YoY
|
| Net Income |
-8.09B
est: -13.27B (+39.0%)
|
31.09B
est: 37.33B (-16.7%)
|
50.13B
est: 37.50B (+33.7%)
|
45.56B
est: 45.27B (+0.6%)
|
45.06B
est: 45.59B (-1.2%)
|
25.25B
est: 34.04B (-25.8%)
|
-6.66B
est: 1.68B (-497.5%)
|
23.16B
est: 32.12B (-27.9%)
|
-17.70B
est: -16.34B (-8.3%)
|
-11.71B
est: 13.49B (-186.8%)
|
28.35B
est: 47.55B (-40.4%)
|
-30.70B
-32.92B – -28.49B
-164.6% YoY
|
19.60B
11.18B – 35.96B
+163.8% YoY
|
19.94B
16.04B – 24.32B
+1.7% YoY
|
19.93B
18.54B – 22.31B
0.0% YoY
|
25.68B
24.00B – 27.73B
+28.8% YoY
|
| SGA |
138.64B
est: 154.31B (-10.2%)
|
147.92B
est: 155.89B (-5.1%)
|
149.18B
est: 146.02B (+2.2%)
|
148.17B
est: 163.69B (-9.5%)
|
154.05B
est: 174.21B (-11.6%)
|
152.84B
est: 168.35B (-9.2%)
|
153.68B
est: 159.45B (-3.6%)
|
163.72B
est: 179.42B (-8.7%)
|
173.97B
est: 202.00B (-13.9%)
|
182.11B
est: 203.13B (-10.3%)
|
239.43B
est: 194.03B (+23.4%)
|
165.17B
163.99B – 166.48B
-14.9% YoY
|
168.90B
163.93B – 178.14B
+2.3% YoY
|
180.86B
168.23B – 193.12B
+7.1% YoY
|
183.41B
181.13B – 185.69B
+1.4% YoY
|
197.08B
187.17B – 209.19B
+7.5% YoY
|
| EPS |
-41.15
est: -68.86 (+40.2%)
|
158.15
est: 193.78 (-18.4%)
|
254.91
est: 194.68 (+30.9%)
|
231.26
est: 234.98 (-1.6%)
|
232.39
est: 236.67 (-1.8%)
|
131.63
est: 176.68 (-25.5%)
|
-34.71
est: 8.70 (-499.1%)
|
120.58
est: 166.71 (-27.7%)
|
-92.04
est: -84.69 (-8.7%)
|
-60.85
est: 70.07 (-186.8%)
|
147.15
est: 245.07 (-40.0%)
|
-158.23
-170.87 – -147.89
-164.6% YoY
|
99.86
58.03 – 186.68
+163.1% YoY
|
101.85
83.28 – 126.23
+2.0% YoY
|
105.65
96.25 – 115.82
+3.7% YoY
|
133.30
124.59 – 143.95
+26.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.31% | 1.20M | 0.58% |
| 2 | Avantis International Small Cap Value ETF AVDV | 0.29% | 55.19M | 0.36% |
| 3 | iShares MSCI Japan Small-Cap ETF SCJ | 0.13% | 346.8K | 0.50% |
| 4 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.13% | 755.1K | 0.58% |
| 5 | Xtrackers FTSE Developed ex US Multifactor ETF DEEF | 0.12% | 67.8K | 0.24% |
| 6 | FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund TLTD | 0.11% | 729.1K | 0.41% |
| 7 | WisdomTree International SmallCap Dividend Fund DLS | 0.11% | 1.13M | 0.58% |
| 8 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.11% | 454.1K | 0.48% |
| 9 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.10% | 1.06M | 0.39% |
| 10 | Vanguard Global Value Equity Active ETF VVLU.AX | 0.09% | 779.3K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Akimoto Uchikawa | President, Chief Executive Officer & Representative Director | 112M | male |
| Fumiaki Sakurai | Group Executive Officer & Chief Human Resources Officer | — | male |
| Hiroshi Uno | Senior Exec.Officer, GM & President of Healthcare Business Group | — | male |
| Ichiro Kitano | Corporate Officer and Chief Production, Engineering & Procurement Officer | — | — |
| Masanori Shimai | CFO & Director | — | male |
| Miho Fujii | Corporate Officer, Chief Sustainability Officer & Corporate Secretary | — | — |
| Noboru Yamanishi | Chief Production, Engineering & Procurement Officer and Executive Officer | — | male |
| Noriko Hidaka | Head of Diversity Promotion Office | — | — |
| Tsunehiro Ogawa | Chief Officer of Special Project, Senior Corporate Project Officer & Teijin Group Executive Officer | — | — |
| Tsutomu Igawa | Corporate Officer & Chief Global Administration Officer | — | — |
| Yuji Nakahara | Corporate Officer, Director & Chief Technology Officer | — | male |
| Yukihiro Funyu | Corporate Officer & Chief Digital Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3401.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
